As we did not assess other potential μ-opioid receptor agonist-induced adverse effects (e.g. respiratory depression, bowel dysfunction, etc.), we cannot speculate on the extent to which NET and SERT inhibition would influence the overall tolerability profile of the drug combinations studied. The gene discussed is SLC6A2; the disease is bowel dysfunction.